Publication:
A transient early hbv-dna increase during peg-ifnα therapy of hepatitis d indicates loss of infected cells and is associated with hdv-rna and hbsag reduction

dc.contributor.authorAnastasiou, Olympia E.
dc.contributor.authorYurdaydin, Cihan
dc.contributor.authorMaasoumy, Benjamin
dc.contributor.authorHardtke, Svenja
dc.contributor.authorCaruntu, Florin Alexandru
dc.contributor.authorCurescu, Manuela G.
dc.contributor.authorYalcin, Kendal
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorErhardt, Andreas
dc.contributor.authorLuth, Stefan
dc.contributor.authorPapatheodoridis, George, V
dc.contributor.authorRadu, Monica
dc.contributor.authorLiebig, Stephanie
dc.contributor.authorBantel, Heike
dc.contributor.authorBremer, Birgit
dc.contributor.authorManns, Michael P.
dc.contributor.authorCornberg, Markus
dc.contributor.authorWedemeyer, Heiner
dc.contributor.buuauthorGürel, Selim
dc.contributor.buuauthorGÜREL, SELİM
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi
dc.contributor.researcheridHLH-8209-2023
dc.date.accessioned2024-07-09T07:40:45Z
dc.date.available2024-07-09T07:40:45Z
dc.date.issued2020-12-12
dc.description.abstractHBV-DNA levels are low or even undetectable in the majority HDV-infected patients. The impact of PEG-IFN alpha on HBV-DNA kinetics in HDV-infected patients has not been studied in detail. We analysed data of a prospective treatment trial where 120 HDV-RNA-positive patients were randomized to receive PEG-IFN alpha-2a plus tenofovir-disoproxil-fumarate (PEG-IFN alpha/TDF, n = 59) or placebo (PEG-IFN alpha/PBO; n = 61) for 96 weeks. At week 96, HBV-DNA was still quantifiable in 71% of PEG-IFN alpha/PBO-treated patients but also in 76% of PEG-IFN alpha/TDF-treated patients, despite low HBV-DNA baseline values. Surprisingly, a transient HBV-DNA increase between weeks 12 and 36 was observed in 12 in PEG-IFN alpha/TDF-treated and 12 PEG-IFN alpha/PBO-treated patients. This increase was positively associated with HBsAg loss [(P = 0.049, odds ratio (OR) 5.1] and HDV-RNA suppression (P = 0.007, OR 4.1) at week 96. Biochemical markers of cell death (M30 and ALT) were higher during the HBV-DNA peak but no distinct systemic immune pattern could be observed by screening 91 soluble inflammatory markers. In conclusion, an early increase in HBV-DNA during PEG-IFN alpha-2a therapy occurred in more than 20% of patients, even in TDF-treated patients. This transient HBV-DNA rise may indicate PEG-IFN alpha-induced cell death and lead to long-term HDV-RNA suppression and HBsAg loss.
dc.description.sponsorshipHepNet Study-House (German Center for Infection Research)
dc.description.sponsorshipHepNet Study-House (German Ministry for Education and Research)
dc.description.sponsorshipHepNet Study-House (German Liver Foundation)
dc.identifier.doi10.1111/jvh.13439
dc.identifier.endpage419
dc.identifier.issn1352-0504
dc.identifier.issue2
dc.identifier.startpage410
dc.identifier.urihttps://doi.org/10.1111/jvh.13439
dc.identifier.urihttps://hdl.handle.net/11452/43069
dc.identifier.volume28
dc.identifier.wos000597760100001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley
dc.relation.journalJournal Of Viral Hepatitis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTenofovir disoproxil fumarate
dc.subjectD virus
dc.subjectReplication
dc.subjectCombination
dc.subjectInduction
dc.subjectResponses
dc.subjectKinetics
dc.subjectAdefovir
dc.subjectInnate
dc.subjectDrug
dc.subjectHbv
dc.subjectHepatitis b
dc.subjectHepatitis d
dc.subjectInterferon
dc.subjectViral kinetics
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectGastroenterology & hepatology
dc.subjectInfectious diseases
dc.subjectVirology
dc.titleA transient early hbv-dna increase during peg-ifnα therapy of hepatitis d indicates loss of infected cells and is associated with hdv-rna and hbsag reduction
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationd7a9ea11-69fc-4122-a365-8fb2123512e6
relation.isAuthorOfPublication.latestForDiscoveryd7a9ea11-69fc-4122-a365-8fb2123512e6

Files

Collections